IGMS (IGM Biosciences) Total Liabilities : $225.56 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Total Liabilities?

IGM Biosciences's Total Liabilities for the quarter that ended in Sep. 2024 was $225.56 Mil.

IGM Biosciences's quarterly Total Liabilities declined from Mar. 2024 ($214.88 Mil) to Jun. 2024 ($214.14 Mil) but then increased from Jun. 2024 ($214.14 Mil) to Sep. 2024 ($225.56 Mil).

IGM Biosciences's annual Total Liabilities increased from Dec. 2021 ($53.22 Mil) to Dec. 2022 ($226.24 Mil) but then declined from Dec. 2022 ($226.24 Mil) to Dec. 2023 ($220.18 Mil).

IGM Biosciences Total Liabilities Historical Data

The historical data trend for IGM Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences Total Liabilities Chart

IGM Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

21.12

26.82

53.22

226.24

220.18

IGM Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															220.49	220.18	214.88	214.14	225.56

IGM Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IGM Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	42.481	+	(34.672	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	143.024	+	0)
	=	220.18

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	423.411	-	203.234
	=	220.18

IGM Biosciences's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	43.964	+	(39.162	+	0.554
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	141.881	+	0)
	=	225.56

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	304.508	-	78.947
	=	225.56

IGM Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

IGM Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (NAS:IGMS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

325 East Middlefield Road, Mountain View, CA, USA, 94043

Website

https://www.igmbio.com

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Executives

Lisa Lynn Decker	officer: Chief Business Officer	C/O ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Steven Weber	officer: Principal Accounting Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Chris H Takimoto	officer: Chief Medical Officer	C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Misbah Tahir	officer: Chief Financial Officer	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Fred Schwarzer	director, officer: CEO and President	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Bruce Keyt	officer: Chief Scientific Officer	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
George Gauthier	officer: Chief Commercial Officer	C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Thompson Elizabeth H.z.	director	C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Jakob Haldor Topsoe	director, 10 percent owner	325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Christina Teng Topsoe	director, 10 percent owner	325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Michael D Loberg	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803